Alembic Pharmaceuticals Share Price | Alembic Pharmaceuticals Stock Screener
APLLTD
Pharmaceuticals
Share Price NSE
₹797.60
▼
-0.75 (-0.09%)
Share Price BSE
₹796.50
▲
2.45 (0.31%)
As of July 24, 2026, the Alembic Pharmaceuticals share price (NSE: APLLTD) is ₹797.60 on NSE and ₹796.50 on BSE, down 0.09% from the previous close, with shares trading between ₹787.40 and ₹803.10, and a 52-week range of ₹646.55–₹1,013.20.
Analyse APLLTD price trends and track historical price performance.
Use the Alembic Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Alembic Pharmaceuticals Market Cap
₹16,383.54 Cr.
APLLTD P/E Ratio (TTM)
24.66
Alembic Pharmaceuticals P/B Ratio
2.92
EPS (TTM)
₹34.33
Dividend Yield
1.43%
Debt to Equity
0.25
APLLTD 52 Week High
₹1013.20
Alembic Pharmaceuticals 52 Week Low
₹646.55
Operating Margin
11.00%
Profit Margin
10.78%
APLLTD Revenue (TTM)
₹1,874.00
EBITDA
₹230.00
Net Income
₹202.00
Total Assets
₹8,763.00
Total Equity
₹5,675.00
Alembic Pharmaceuticals Share Price Chart
Screen Alembic Pharmaceuticals share price with an interactive chart. Analyse APLLTD price trends and volatility across different timeframes.
Alembic Pharmaceuticals Company Profile - Fundamental Screener
Screen Alembic Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for APLLTD shares.
Alembic Pharmaceuticals is an India-based company that manufactures and markets generic pharmaceutical products globally. It operates in India Formulations, International Generics, and Active Pharmaceutical Ingredients (API) segments. The company has state-of-the-art research and manufacturing facilities approved by regulatory authorities, including the US FDA. Alembic produces a range of generics across...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Chirayu R Amin
ISIN
INE901L01018
Alembic Pharmaceuticals Balance Sheet Screener
Screen APLLTD balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 8,763 | 7,773 | 6,446 | 6,183 | 7,122 | 6,709 | 5,989 | 4,778 | 3,941 | 2,689 |
| Current Assets | 4,573 | 4,088 | 3,079 | 2,910 | 2,861 | 2,652 | 2,463 | 1,958 | 1,825 | 1,373 |
| Fixed Assets | 3,764 | 2,524 | 2,547 | 2,398 | 1,798 | 1,788 | 1,552 | 1,159 | 993 | 799 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 500 | 171 | 172 | 175 | 168 | 361 | 1,047 | 570 | 576 | 94 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 5,675 | 5,190 | 4,818 | 4,371 | 5,238 | 5,067 | 3,190 | 2,718 | 2,220 | 1,902 |
| Share Capital | 39 | 39 | 39 | 39 | 39 | 39 | 38 | 38 | 38 | 38 |
| Reserves & Surplus | 5,636 | 5,152 | 4,779 | 4,331 | 5,198 | 5,028 | 3,182 | 2,681 | 2,182 | 1,865 |
Alembic Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Alembic Pharmaceuticals income statement and profit fundamentals.
Analyze APLLTD quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Alembic Pharmaceuticals share price evaluation.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,874 | 1,784 | 1,717 | 1,919 | 1,892 | 1,521 | 1,564 | 1,678 | 1,703 | 1,407 | 1,498 | 1,605 | 1,634 | 1,426 | 1,263 |
| Expenses | 1,645 | 1,498 | 1,430 | 1,595 | 1,627 | 1,257 | 1,325 | 1,409 | 1,433 | 1,203 | 1,288 | 1,387 | 1,364 | 1,268 | 1,255 |
| EBITDA | 230 | 286 | 287 | 324 | 265 | 263 | 239 | 270 | 270 | 205 | 210 | 218 | 269 | 158 | 9 |
| Operating Profit % | 11.00% | 15.00% | 16.00% | 17.00% | 13.00% | 17.00% | 15.00% | 15.00% | 15.00% | 14.00% | 13.00% | 13.00% | 16.00% | 10.00% | 1.00% |
| Depreciation | 89 | 69 | 74 | 76 | 80 | 70 | 69 | 71 | 70 | 74 | 66 | 68 | 69 | 123 | 67 |
| Interest | 23 | 25 | 24 | 24 | 23 | 11 | 13 | 19 | 22 | 14 | 14 | 16 | 15 | 7 | 9 |
| Profit Before Tax | 119 | 192 | 190 | 224 | 162 | 183 | 157 | 180 | 178 | 116 | 130 | 135 | 185 | 29 | -67 |
| Tax | -83 | 35 | 37 | 40 | 30 | 5 | 23 | 27 | 40 | -36 | 9 | -2 | 4 | 7 | -2 |
| Net Profit | 202 | 157 | 154 | 184 | 132 | 178 | 135 | 153 | 138 | 153 | 121 | 137 | 180 | 22 | -66 |
| EPS | 10.31 | 7.98 | 7.85 | 9.40 | 6.76 | 9.07 | 6.84 | 7.79 | 7.01 | 7.76 | 6.14 | 6.95 | 9.23 | 1.11 | -3.35 |
Alembic Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen APLLTD cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 88 | 803 | 724 | 552 | 1,463 | 449 | 812 | 312 | 329 | 948 |
| Investing Activities | -568 | -321 | -448 | -372 | -840 | -731 | -756 | -884 | -486 | -307 |
| Financing Activities | 444 | -438 | -262 | -217 | -597 | 155 | 59 | 503 | -129 | -224 |
| Net Cash Flow | -37 | 45 | 14 | -37 | 26 | -127 | 115 | -69 | -286 | 417 |
Alembic Pharmaceuticals Shareholding Pattern Screener
See Alembic Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings.
Check Alembic Pharmaceuticals promoter holding and ownership changes for APLLTD on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 69.74% | 69.67% | 69.67% | 69.74% | 69.74% | 69.61% | 69.61% | 69.61% |
| FII Holding | 4.25% | 3.94% | 3.96% | 4.05% | 4.24% | 4.46% | 4.32% | 3.94% |
| DII Holding | 16.18% | 16.43% | 16.46% | 16.30% | 16.17% | 15.38% | 15.47% | 16.05% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 6.86% | 7.07% | 7.01% | 6.93% | 6.87% | 7.41% | 7.48% | 7.36% |
| Other Holding | 2.96% | 2.88% | 2.89% | 2.99% | 2.98% | 3.14% | 3.13% | 3.04% |
| Shareholder Count | 86,432 | 91,336 | 89,013 | 89,969 | 87,000 | 76,567 | 74,829 | 91,429 |
Alembic Pharmaceuticals Share Dividend Screener - Share Yield Analysis
Check Alembic Pharmaceuticals dividend history with payout and yield data.
View Alembic Pharmaceuticals dividend details including ex-dates and amounts for APLLTD stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹11.00 | 1.66% |
| 2024-March | ₹11.00 | 1.18% |
| 2023-March | ₹8.00 | 0.81% |
| 2022-March | ₹10.00 | 2.13% |
| 2021-March | ₹14.00 | 1.89% |
| 2020-March | ₹10.00 | 1.04% |
| 2019-March | ₹5.50 | 1.03% |
| 2018-March | ₹4.00 | 0.74% |
| 2017-March | ₹4.00 | 0.73% |
Alembic Pharmaceuticals Stock Index Membership
See which indices include Alembic Pharmaceuticals stock.
Check APLLTD index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX MSL400
BSE INDEX SML250
BSE INDEX SMLCAP
NIFTY 500
NIFTY MIDSML 400
NIFTY MIDSML HLTH
NIFTY SMALLCAP250 MOMENTUM QUALITY 100
NIFTY SMLCAP 250
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MULTICAP
NIFTY500 SHARIAH
Alembic Pharmaceuticals Market Events Screener - Corporate Actions
Get Alembic Pharmaceuticals corporate actions including splits, bonuses, and buybacks.
Check Alembic Pharmaceuticals stock events that may affect APLLTD share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-05 | 2026-08-05 | Annual General Meeting | NA | 3.22% |
| 2026-07-29 | 2026-07-29 | Dividend | ₹ 12.00 /share | 7.15% |
| 2026-05-15 | 2026-05-15 | Quarterly Result Announcement | NA | 4.71% |
| 2026-02-05 | 2026-02-05 | Quarterly Result Announcement | NA | 3.71% |
| 2025-11-04 | 2025-11-04 | Quarterly Result Announcement | NA | -0.92% |
| 2025-08-05 | 2025-08-05 | Annual General Meeting | NA | -1.57% |
| 2025-08-05 | 2025-08-05 | Quarterly Result Announcement | NA | -6.22% |
| 2025-07-29 | 2025-07-29 | Dividend | ₹ 11.00 /share | 10.49% |
| 2025-05-06 | 2025-05-06 | Quarterly Result Announcement | NA | 6.54% |
| 2025-02-03 | 2025-02-03 | Quarterly Result Announcement | NA | -9.02% |
| 2024-11-07 | 2024-11-07 | Quarterly Result Announcement | NA | -3.68% |
| 2024-07-22 | 2024-07-22 | Annual General Meeting | NA | 27.73% |
| 2024-07-15 | 2024-07-15 | Dividend | ₹ 11.00 /share | -1.72% |
| 2023-07-28 | 2023-07-28 | Dividend | ₹ 8.00 /share | 30.61% |
| 2022-08-17 | 2022-08-18 | Dividend | ₹ 10.00 /share | -16.05% |
Alembic Pharmaceuticals Competitors Screener - Peer Comparison
Screen APLLTD competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 470,030 | 40.78 | 61,674 | 12.69% | 11,565 | 67.08 |
| Divis Laboratories | 194,004 | 75.69 | 11,067 | 13.95% | 2,568 | 71.64 |
| Torrent Pharmaceuticals | 190,667 | 79.19 | 13,886 | 20.34% | 2,138 | 65.32 |
| Cipla | 115,385 | 30.16 | 29,045 | 2.24% | 3,870 | 55.65 |
| Zydus Life Science | 115,113 | 22.33 | 27,658 | 17.64% | 5,026 | 60.58 |
| Lupin | 114,500 | 21.16 | 29,039 | 26.75% | 5,356 | 59.41 |
| Mankind Pharma | 106,227 | 54.68 | 14,636 | 14.85% | 1,938 | 59.45 |
| Dr Reddys Laboratories | 100,778 | 24.56 | 35,059 | 3.90% | 4,158 | 35.59 |
| Aurobindo Pharma | 89,897 | 25.88 | 33,385 | 3.21% | 3,376 | 55.50 |
| Laurus Labs | 85,686 | 94.61 | 6,868 | 22.01% | 890 | 63.63 |
Alembic Pharmaceuticals Company Announcements - News Screener
Screen APLLTD latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. | - | |
| 2026-07-19 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-18 | Specimen Copy Of The Letter Sent To The Shareholders Under Regulation 36(1)(B) Of SEBI LODR | - |
| 2026-07-18 | Intimation Of Record Date For Payment Of Dividend On Equity Shares For The Financial Year Ended 31St March 2026. | - |
| 2026-07-18 | Business Responsibility and Sustainability Reporting (BRSR) | - |
| 2026-07-18 | Reg. 34 (1) Annual Report. | - |
| 2026-07-18 | Submission Of Notice Of The 16Th Annual General Meeting Of The Company. | - |
| 2026-07-16 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-07-15 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-01 | Announcement under Regulation 30 (LODR)-Credit Rating | - |
| 2026-06-26 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-06-26 | Closure of Trading Window | - |
| 2026-06-26 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-06-26 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-06-19 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-06-19 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-06-19 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-06-19 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-06-18 | Announcement under Regulation 30 (LODR)-Change in Directorate | - |
| 2026-06-12 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |